Arecor Therapeutics PLC (LSE:AREC) has reinforced its intellectual property around its lead concentrated insulin, days after completing a fundraising of about £5.13m. On 15 October 2026 the clinical-stage biotech said it had been granted patents in Europe and the United States covering the use of AT278 in automated insulin delivery systems, each extending protection to at least 2039, along with an Indian patent covering the product's composition.

What the company does

Arecor develops therapeutics for diabetes, obesity and other cardiometabolic diseases. Its main focus is two insulin candidates: AT278, an ultra-concentrated, ultra-rapid-acting insulin at 500 units per millilitre, and AT290, at 200 units per millilitre. The company believes concentrated insulins could enable longer-wear, smaller and fully closed-loop insulin pump systems. It is also developing an oral delivery platform for peptides, with a GLP-1 receptor agonist as its first target.

Latest developments

Interim results published on 30 September showed that partnering discussions with several insulin pump companies have reached term sheet stage. Chief executive Dr Sarah Howell said the aim is to bring a next-generation insulin and pump system to people with type 1 and type 2 diabetes. AT278 is being co-developed with Sequel Med Tech towards Phase 2 readiness, and the company reported continued positive interactions with the US Food and Drug Administration on Phase 2 study design. Data on AT278 were published in a peer-reviewed journal in August.

Alongside the interims, Arecor raised about £5.0m through a placing of 7,352,941 shares at 68p each, a price representing a small premium to its 60-day volume-weighted average. A retail offer added around £0.13m. Proceeds will support partnership negotiations and critical-path development, including data for a Phase 2 Investigational New Drug application.

Financial and dividend picture

Revenue for the first half fell to about £0.2m from £1.0m, as royalty income ended after the company sold its royalty rights to Ligand in September 2025. That deal provided US$7m upfront and up to US$4m in milestones, two of which have been received. The loss after tax from continuing operations was £3.0m. Cash, cash equivalents and short-term investments totalled £3.2m at 30 June.

The board expects full-year revenue of around £0.3m and a loss after tax of £5.5m. Before the fundraising, existing cash funded the company to April 2027; the new money is expected to extend the runway to December 2027. Arecor does not pay a dividend.

Sector and index context

Arecor is among the life sciences companies in the FTSE AIM All Share Index. Diabetes technology is a large and competitive field, with automated insulin delivery systems gaining ground. The company estimates that patients with the highest unmet need represent a US insulin revenue opportunity of roughly US$3bn. Its subsidiary Tetris Pharma, whose operations the group decided to cease in January 2025, is now reported as a discontinued operation, leaving the business focused on its development pipeline.

Key risks

Arecor's future depends heavily on securing a commercial partner and advancing AT278 through clinical development, both of which are uncertain. Its cash runway, while extended, remains limited, and further funding may be required. Regulatory delays or disappointing trial results would weigh on prospects, and larger insulin makers could develop competing products.

What to watch next

Investors will watch for any agreement emerging from the term sheet discussions with pump companies, a definitive agreement with Sequel, preparation of the Phase 2 application, and remaining milestone payments from Ligand. The newly granted patents give Arecor (LSE:AREC) a firmer footing in those partnering talks, and progress towards the clinic will shape how far the extended runway can carry the programme.